COMPANY
Clinical Phase 2
Profile checked Oct 10, 2026
Keywords: Autoimmune Diseases Cardiovascular Disorders Diabetes Complications Integumentary Disease Musculoskeletal Disorders Neurodegenerative Disorders Neurologic Disorders Pulmonary Disorders Sexual Dysfunction Urologic Disorders Viral Illness Covid19 Prophylaxis PrimePro™/ PrimeMSK™ PrimePro
Timeline
- Trial start Phase 1/Phase 2: Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions source ↗
- Trial start Phase 1: Mesenchymal Stem Cells for the Treatment of COVID-19 source ↗
Upcoming milestones
- Jul 9, 2030 (ESTIMATED) · Phase 1/Phase 2 · Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions · NCT04684602
Estimated primary completion per ClinicalTrials.gov. Dates move.
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT04684602 | Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions | Phase 1/Phase 2 | Recruiting | Jul 9, 2020 | Jul 9, 2030 (estimated) |
| NCT04573270 | Mesenchymal Stem Cells for the Treatment of COVID-19 | Phase 1 | Completed | Apr 24, 2020 | Aug 20, 2020 (actual) |
